Kardiologie Vinohrady s.r.o.
- Address
- Vodickova 1935/38, Nove Mesto, 110 00 Prague, Czechia
Kardiologie Vinohrady s.r.o. - Cardiovascular Research Center
Kardiologie Vinohrady s.r.o. is a specialized cardiology research center dedicated to advancing the treatment and management of acute cardiovascular conditions. The center focuses on innovative therapeutic approaches for patients at high risk of cardiovascular events, with particular emphasis on acute myocardial infarction (AMI) and secondary prevention strategies.
- Novel antiplatelet therapies for acute myocardial infarction
- Self-administered emergency cardiovascular medications
- Secondary prevention in high-risk cardiac patients
The center's research portfolio demonstrates expertise in evaluating breakthrough interventions such as selatogrel, investigating clinical efficacy outcomes in patients experiencing recurrent cardiac events. Through participation in international outcome studies, Kardiologie Vinohrady contributes to the development of patient-centered emergency treatment protocols that enable rapid intervention at the onset of symptoms suggestive of AMI.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Amgen Inc.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kardiologie Vinohrady s.r.o.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 2 | Unknown | 2024-10-18 | 2025-08-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.